This painting company has been stable, but they have seen sustained growth and have been one of the fastest growing small business painting companies in the Vancouver/Portland area. Starting in 2013, annual had already eclipsed half a million by 2019. With a work-from-home office, this business provides the ability to manage safely out of your own home or to be able to choose your ideal location to rent. Strong customer ratings and consistently high levels of service have made this an ideal business for anyone looking to establish a presence in the painting industry or to expand your current painting business territory and customer base. Detailed Information Employees:2 FTE Support & Training: Seller will negotiate a transition period Reason for Selling: Relocation

Patented Universal Tumor-Targeting Drug Delivery Platform Co. This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company's ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company's ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to "universally" target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers. The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin. The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations. As the Company's platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI. The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); follwed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company's valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approx. 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support. NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners. Detailed Information Competition: Trying to improve existing therapies and develop novel approaches to hard to treat cancers. Growth & Expansion: Huge market potential. Financing: If the price and deal structure is right. Support & Training: Transition team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .

Our client is a world leader in iris recognition technology with a large production capacity based in USA. They are a multinational corporation with a robust track record of selling its best-selling, award winning technology products worldwide. Clients include the UN, the US Department of Homeland Security, US Navy, US Marine Corps, the governments of India the Philippines, Kenya, and in the private Sector Northrop Grumman, InCadence and numerous others. The company has and continues to develop an ever-increasing range of technical applications for its products in a very large and rapidly growing market. Applications range from numerous physical security applications to blockchain and cryptocurrency applications. This firm owns 28 patents (24 registered and 4 pending) for its proprietary "iris matching algorithm, iris recognition in bright outdoors under sunlight" technology and security technology. Our client also has world-leading iris recognition technology to crypto wallet, which dramatically improves the security and convenience of digital assets on blockchain. In addition to multiple patents, our client also owns 10 trademarks. Our client's iris recognition algorithm was evaluated as the world's best technology at IREX I of NIST in the USA, and its excellence has been proven. They are one of few companies to provide a complete solution including SW and HW from iris image scanner to matching SDK on server with the world's best technology. This business has global references for the National ID projects of the Indian and Philippine governments They achieved the No.1 market share, including UN-affiliated organizations such as UNHCR and WFP, and these markets are expanding worldwide. Our client's tech and related device is the only iris camera system satisfying MOSIP SBI 2.0 requirements for authentication (many countries are utilizing the MOSIP platform for their National ID systems). Our client's unique and powerful technologies are registered and protected by global patents, enabling stable business development and expansion. The company offers a total data infrastructure solution (large or small data requirements) for Web 3.0 (Web 3.0 is the approach for a new iteration of the World Wide Web which incorporates concepts such as decentralization, blockchain technologies, and token-based economics). Their technologies are based on Blockchain, IPFS, and distributed storage of private keys (IPFS is a distributed file system that seeks to connect all computing devices with the same system of files. This means data can be securely shared for Know Your Customer and Anti-Money Laundering (KYC and AML) needs. This meets information sharing protocols between service providers and will lead to a new and open data economy. The ramifications are complete security for Bank information, Financial Transaction Data, Driving Data, SNS Contents, Health Information, Government/Education Certification, Insurance Information in short data stemming from virtually any source. Confidential Information Memorandum (CIM) is available upon receipt of our short online NDA. Financing: If the price and deal structure is right. Support & Training: Provided at no charge to enable a smooth transition Reason for Selling: World-wide expansion

The Company provides IT and telecommunications solutions, specializing in IT security, network infrastructure, software development, enterprise management, and systems support. It delivers global telecommunications through fiber and other networks and offers program management, telecom licensing, and continuity of operations support. Clients are primarily Department of Defense agencies and sub-agencies, with licensed technicians and small business set-aside contracts. The largest contract accounts for 27.0% of year-to-date revenue, with DISA contracts totaling 44.8%. The Company has consistently received “Excellent” ratings in CPARS and operates from leased office space with a secure, government-inspected facility for sensitive document storage. Confidentiality is a concern for the Seller as he seeks just the right buyer, and so the location information provided in the ad is that of the broker, and not of the Business.Business location and name will be shared once a qualified Buyer prospect is vetted. NDA is required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

Our client is an exploding, music talent agency--yearly revenue has increased since inception, at a percentage rate year over year of approximately 600%. Our client is a 'positive hustle and hard work ethic' music talent business built on the sheer effort of bringing music artists to the performance stage. Built from the ground up, the business foundation has been developing emerging performance talent while using well-known artists to kick in larger revenue when possible. A great source of success has come from acquiring visas for in-demand international artists and bringing them to the US marketplace. Our client brings the following: - 80+ acts signed to exclusive contracts (1-to-2-year terms) - Robust artist scouting protocol signing on average 3 acts a week - Can be staffed with agents anywhere in the world - Access to the nation's largest contact book of venues, talent buyers, and promoters - Non-exclusive booking rights for Snoop Dogg, Ice Cube, OT Genasis, Xzibit, Warren G, Bizzy Bone, B.o.B, and Bone Thugs N Harmony - Over 1,000 performances booked in half of a calendar year (2022) - Artists in several genres are actively leaving their current booking agencies in favor of coming onto our client's roster. Our client has been awarded positive recognition by a large majority of its artists as well as publications like MoneyGeek, DMC World, Pollstar, Gigwell, and Shoutout Atlanta. The Company's key paradigm is to find and monetize talent. Our client's team is constantly scouting new talent locally and internationally and bringing them to the marketplace. Our client consults on all aspects of artist growth from graphic design and social media strategy to music guidance and consulting. Urgency drives the foundations and operations of Our client's enterprise. This has proven to be a successful strategy, as month over month, our client is showing exceptional growth: in 2022 up to July, the Company is averaging $86,500 per month in gross revenue. NDA is required to secure a comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Growth/Expansion: In CIM. Financing: Seller does not wish to finance. Support & Training: Provided at no charge to enable a smooth transition. Reason for Selling: other projects.

The Company is a diversified business with multiple divisions, but its HVAC/Plumbing division is the cornerstone of operations. This division has built a strong reputation in its regional market by delivering trusted residential services, including plumbing and HVAC system installations, water service and treatment, well pump solutions, and recurring seasonal winterization. Its reputation is reinforced by decades of reliable service to both permanent and seasonal homeowners, positioning the business as the go-to resource in the area. With EPA-certified technicians and dedicated office staff for dispatch and billing, the HVAC/Plumbing division combines technical expertise with responsive customer support, ensuring consistent service quality and long-standing client relationships. In addition, the Company operates hardware, parts, and equipment rental divisions, providing customers with a broad selection of tools, supplies, and repair solutions to complement its core service offerings. NDA is required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

The Company operates in the healthcare technology space with a focus on addressing gaps in dementia and Alzheimer’s care. The company has built an ecosystem where data is collected from caregivers and patients in real-time and pushed into physicians’ EHR/EMR systems to monitor the effectiveness of the prescribed treatment plan. Alzheimer’s Disease and other dementia is the first condition that the platform will be focused on. Its platform supports physicians in managing patients through tools that enable remote monitoring and data collection, allowing for more continuous oversight rather than episodic intervention. The business generates revenue through a combination of public healthcare reimbursements and collaborations with pharmaceutical and research entities. Its model emphasizes integrating digital health solutions into clinical workflows to improve patient tracking and care coordination. The Company’s target users include healthcare providers, caregivers, and researchers working with aging populations impacted by cognitive decline. NDA is required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

Our client operates a lean, high-margin B2B lead-generation platform dedicated to the Internet of Things sector. By leveraging a permission-based community of over 60,000 vetted IoT decision-makers and a LinkedIn Group of 20,000+ approved professionals, they deliver turnkey sponsored webinars, white-paper campaigns, and targeted email blasts—providing technology vendors with consistently qualified leads while maintaining minimal overhead through a fully remote, contractor-driven model. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.